• Strategic Technologies

bioProcessUK: Where next for sustainable biotechnologies?

Sustainability affects us all. It’s not just centred on one country or one industry, it is a collective societal goal that we should all be working towards so that we, and our flora and fauna neighbours can safely co-exist on Earth well into the future.

Brainomix announces new partnership with Pixyl to expand its offering with multiple sclerosis solution

Brainomix to distribute Pixyl.Neuro.MS Software as a Service (SaaS) solution exclusively in the UK and Ireland, the Nordics and key markets across Eastern Europe. The emergence of disease-modifying drugs now offers more personalized treatment of multiple sclerosis, a neurological disorder that affects more than 2.3 million people worldwide. This has elevated the role of MRI in supporting both the diagnosis and ongoing disease monitoring and treatment response, opening the door for AI-powered solutions such as Pixyl’s Neuro.MS software to improve diagnosis and speed up treatment.

TechBio innovator spotlight: BIOS

BIOS is leveraging the nervous system to inform treatments and deliver therapies for chronic conditions. The company uses AI and machine learning technology to tap into the nervous system which acts as the controlling, regulatory and communication system for the body, connecting all organs to the brain and spinal cord.

Touchlight signs license agreement with Voyager for use of Touchlight’s DNA technology in Voyager’s capsid discovery platform

Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a patent license agreement with Voyager Therapeutics, Inc., a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids.

CEO Update | 28 November 2022

Thank you to all who have joined our BIA campaign to seek a solution to cuts in SME R&D tax credits introduced in the Autumn Statement. Today I was able to raise our concerns personally by handing a letter signed by over 300 CEOs to the Health Secretary and the Business Secretary at a meeting in Number 10 who assured me that this issue is being taken seriously at the very top of government.

CEO Update | 21 November 2022

A great week of UK life science connectivity at and around the Jefferies conference last week had the rug pulled from under it by government proposals in Thursday’s Autumn Statement to radically cut R&D tax credits for small and medium-sized companies from next April. We were able to provide immediate expert analysis of the implications of this proposal to Treasury officials last week. I will also be raising this with Ministers at the Life Sciences Council next Monday.

Tackling AMR is imperative for the future of medical innovation

​World Antimicrobial Awareness Week (WAAW) is a global campaign celebrated annually to improve awareness and understanding of Antimicrobial Resistance (AMR). In light of WAAW, we've collaborated with SwedenBIO and the International Council of Biotechnology Associations (ICBA) to launch a campaign to spread awareness and eradicate #TheSilentPandemic. Read this blog by Karoline Akerjordet, Chair of the ICBA AMR Working Group and Vice CEO of Pharmiva AB, to understand why tackling AMR is imperative for the future of medical innovation.

TechBio innovator spotlight: NonExomics

Almost all current therapies target proteins that are made by two percent of the genome, known as the exome, but NonExomics has demonstrated and validated that the rest of the 98% of the human genome, called the nonexome, can also code and make proteins. Importantly, 80–90% of all disease mutations lie in the nonexome and hence to cure diseases it is important to understand the consequences of these mutations to the proteins discovered by NonExomics that are made in the nonexome.

UK Supplier expands to provide Chemically Defined & Serum-Free Cell Media Solutions for the Cell and Gene Therapy Industry

BioPharma Dynamics, a leading life sciences solution provider, proudly expand their extensive portfolio for the Cell & Gene Therapy market to offer a range of chemically defined T-Cell Media, DMSO-Free Cryopreservation Solutions, and Recombinant Growth Factors.

Visionable and Brainomix announce strategic partnership to tackle “bottlenecks” in time-sensitive stroke care pathway

Visionable, a real-time clinical collaboration platform enabling virtual healthcare models, and Brainomix, an AI-powered medtech solutions company, have announced a powerful strategic partnership that is transforming the delivery of stroke care.